Interactive modules by Olga Goodman, MD.Copyright protected · Read termsClose terms

All RheumaView™ interactive modules, quizzes and educational cases are original works developed by Olga Goodman, MD.

Without the author’s prior written permission, you may not copy or republish these modules or their components; extract, reuse or modify their original software code (“engines”); or use that code to build your own modules, quizzes or other products.

You may not claim these works as your own or remove or replace the author’s name or copyright notices. When quoting material, credit Olga Goodman, MD, identify the source and include a direct link to the original.

Free or public access is provided for learning and does not grant permission to copy, adapt or redistribute the materials. Unauthorized use of protected material may constitute copyright infringement. Exceptions and limitations provided by applicable law remain unaffected.

Sharing direct links to the modules is welcome.

© 2026 Olga Goodman, MD. All rights reserved.

Reading research without losing perspective

Chapter 13 · Patients & families

Reading research without losing perspective

New studies can improve care, but a promising mechanism, a trial result and an approved treatment are different steps.

Olga Goodman, MD · Evidence checked: 25 September 2026

What is established

The SpA family shares clinical features while containing meaningful differences. Diagnosis remains a clinical synthesis. Treatment is selected according to the active phenotype and associated conditions. Those foundations should not be replaced by an isolated headline.

What researchers are trying to clarify

Axial involvement in PsA remains an important area of definition and measurement. The international AXIS study adds data, but does not turn every person with psoriasis and back pain into one uniform disease category. Researchers also study earlier recognition, imaging interpretation, treatment prediction and persistent symptoms.

How to read a treatment claim

Ask which patients were studied, which outcome improved, what the comparison was and how long follow-up lasted. A skin response does not establish a spinal response. An exploratory biomarker does not yet provide a reliable individual forecast. Safety, replication and practical applicability matter alongside the size of a benefit.

What ‘new’ means on this page

The evidence review for this module is dated 25 September 2026. It uses established ASAS–EULAR axSpA and EULAR/GRAPPA PsA guidance, with newer work clearly identified. Recommendation dates may differ from publication dates. Approval and access to medicines vary by country and should be checked at the time of a treatment decision.

Sources & further reading
  1. ASAS–EULAR axSpA management recommendations: 2022 update
  2. EULAR PsA pharmacological recommendations: 2023 update, published 2024
  3. GRAPPA treatment recommendations 2021, published 2022
  4. International AXIS study: axial involvement in PsA (2026)
  5. EULAR physical activity recommendations: 2025 update, published 2026

Share this page

FacebookLinkedInXWhatsAppTelegram

Topics: Spondyloarthritis